To use all functions of this page, please activate cookies in your browser.
Innovative Biosensors and Massachusetts Institute of Technology Announce Licensing Agreement for Biosensor Technology
Innovative Biosensors Inc., a privately held pioneering developer of rapid diagnostic technologies, today announced that the Company has obtained an exclusive license for the CANARY(TM) biosensor technology developed at Massachusetts Institute of Technology (MIT) Lincoln Laboratory.
The CANARY(TM) technology, published in the July 11th issue of the Journal Science, uses cells of the immune system which have been engineered to express recombinant antibodies specific to the antigen of interest as well as a protein based emitter molecule in the cell's cytosol. The binding of the antigen to the engineered antibody on the cell's surface results in light emission, detectable in a sensitive and rapid fashion by a small optical detection device. This approach allows for extremely rapid testing of analytes with previously unseen levels of sensitivity and specificity.
Under the terms of the agreement, the license gives Innovative Biosensors exclusive rights to use this technology in the fields of food testing, human and animal clinical diagnostics, and sales to the life science research market.
This license makes Innovative Biosensors the only company allowed to develop, manufacture and sell instruments and kits using the cell based biosensor technology in these fields, in the United States, Canada, Europe, Japan and other countries around the world. Further details of the agreement were not disclosed.
"We are extremely delighted to have obtained rights to this novel and revolutionary technology and will move quickly to commercialize much needed rapid, sensitive and specific assays for the detection of infectious organisms," stated Joe Hernandez, Founder and CEO of Innovative Biosensors. "We are enthusiastic about the use of this technology in biothreat applications related to food testing and clinical diagnostics and in the rapid detection of emerging infectious diseases," added Mr. Hernandez.
"This agreement with Innovative Biosensors is an important milestone in the commercialization of this exciting technology," said Mark Hollis, Ph.D., leader of the Biosensor Technologies Group at MIT Lincoln Laboratory.
- Merck Announces VAR2 Pharmaceuticals as Winner of its Advance Biotech Grant
- HepaRegeniX GmbH achieves successful proof of efficacy in acute liver diseas ...
- Merck acquires a French company
- analytica 2020: Great exhibitor resonance for the autumnal fair
- Novel virtual trade fair for the process industry